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OBJECTIVES: Atherosclerosis is a chronic inflammatory disease. Research has focused on identifying specific
serum biomarkers to detect vulnerable plaques. These markers serve as diagnostic tools for acute coronary
syndrome and assist in identifying high-risk patients. However, the existing data are limited and conflicting.
This study tested the hypothesis that CD137 levels identify patients with acute coronary syndrome who are at a
heightened risk for recurrent cardiac events.
METHODS: The levels of soluble CD137 (sCD137) were measured using ELISA in 180 patients with acute coronary
syndrome and 120 patients with acute chest pain. Platelet activation was assessed by flow cytometry. Receiver
operating characteristic curve analysis was performed to evaluate the prognostic characteristics of sCD137.
RESULTS: The levels of sCD137 were elevated in 75 patients with acute coronary syndromes and 20 patients with
acute chest pain (.35.0 ng/ml). In patients with acute coronary syndrome, elevated sCD137 levels (.35.0 ng/ml)
indicated an increased risk for major adverse cardiovascular events (OR=1.93, 95% CI: 1.39-2.54). Elevated
serum levels of sCD137 and cTnT were correlated with a significantly increased risk of major adverse
cardiovascular events in both groups after 30 days, six months and nine months of follow-up. The increased
sCD137 levels were significantly correlated with the levels of troponin I (r = 0.4799, p,0.001). Importantly, 26
patients with normal cTnI levels had acute coronary syndrome. However, elevated sCD137 levels identified
these patients as a being high-risk subgroup (OR=2.14, 95% CI: 1.25-4.13).
CONCLUSIONS: Elevated sCD137 levels indicate an increased risk of cardiovascular events in patients with acute
coronary syndrome. Soluble CD137 may be a useful prognostic marker or indicator for adverse events in
patients with acute coronary syndrome.
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& INTRODUCTION
Acute coronary syndrome (ACS), including unstable
angina and non-ST and ST segment elevation myocardial
infarction, is the leading cause of mortality and morbidity
worldwide (1,2). Despite the use of electrocardiogram and
biochemical markers to assist in the diagnosis and monitor-
ing of ACS, patients are still misdiagnosed in the emergency
department or suffer an acute coronary event and die
without having presented prior symptoms (3,4). Although
the use of sensitive troponin assays has improved diagnostic
capabilities, additional biomarkers would be particularly
useful for identifying patients who are at long-term risk
after presentation. Several acute-care markers, such as
OX40, PAPP-A, and C-reactive protein, have longer-term
predictive value in patients with ACS (5-6). However, other
at-risk patients may not be identified because none of these
biomarkers indicate unstable plaques. Markers in the
bloodstream, such as troponin and creatine kinase-MB,
indicate myocardial injury but are not necessarily elevated
in patients with unstable angina or early myocardial
infarction. A circulating marker that signifies unstable
plaques in the coronary arteries could provide additional
and powerful diagnostic information for patients with ACS.
This type of marker would also improve the prognosis of
patients with chest pain and may identify those patients
who are at risk for developing ACS.
Several studies have shown that CD137 is expressed in
human atherosclerotic plaques and patients with ACS (8-
10). Jeon et al. (11) recently reported that CD137 (4-1BB)
deficiency reduced atherosclerosis in hyperlipidemic mice.
This information suggests that CD137 is potentially related
to the development of atherosclerotic plaques. However, the
additive predictive value of sCD137 in troponin-negative
ACS patients has not been evaluated. The present study
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assessed whether there is additive diagnostic value by
measuring circulating sCD137 levels in patients with
suspected ACS and normal troponin values at the time of
hospital admission. A cutoff value that could be applied in
routine clinical practice was calculated and validated. The
study also tested the hypothesis that combined assessment
of sCD137 and the validated cTnI marker leads to an
improved prognosis.
& MATERIALS AND METHODS
The study was reviewed and approved by the institutional
review committee, and informed consent was obtained from
all patients and control subjects.
Reagents
A sCD137 ELISA kit from Bender MedSystems (Campus
Vienna Biocenter, Vienna, Austria) was used (detection limit
of 0.1 ng/ml). A troponin I kit was obtained from Triage
and Biosite. A CD61-FITC-conjugated antibody was pur-
chased from Pharmingen.
Patients and control subjects
The trial enrolled 180 patients with ACSwho had recurrent
chest pain at rest in association with electrocardiographic
changes or elevated serum cardiac markers. These patients
had substantial coronary artery disease, as documented by
coronary angiography, with stenosis of at least 70 percent of
the coronary artery diameter at a culprit lesion. All patients
were followed for 30 days, six months and nine months for
major adverse cardiovascular events (MACEs), including
acute myocardial infarction (AMI), sudden death and
recurrent angina. A total of 102 patients with acute chest
pain lasting less than 6 hours and no ST-segment elevation on
electrocardiography were also enrolled. The presence of
coronary artery disease was documented by one of the
following criteria: electrocardiographic evidence of myocar-
dial ischemia (new ST-segment depression or T-wave
inversion) and a history of coronary heart disease (myocar-
dial infarction or coronary revascularization, a positive
exercise stress test or narrowing of at least 50% of the
luminal diameter of a major coronary artery on a current
angiogram). Patients without coronary heart disease had a
normal coronary angiogram. Patients with an infection, a
tumor, or liver or kidney diseases were excluded.
Blood sampling protocol
In ACS patients, blood samples were collected from the
forearm at pre-determined time intervals after admission. In
the patients with acute chest pain, peripheral venous blood
was drawn into blood collection tubes with sodium citrate to
obtain monocytes or without sodium citrate to obtain serum
upon arrival in the emergency room. Peripheral venous blood
mononuclear cells were obtained by Isopaque-Ficoll gradient
centrifugation and placed in plastic flasks. Monocytes were
harvested by scraping and collected in RPMI 1640 medium.
Non-sodium citrate-treated blood was immersed in melting
ice and allowed to clot for 1 h before centrifugation (15006g
for 10 min at 4 C˚). The supernatant was stored at -80 C˚ until
analysis. Samples were only thawed once.
Detection of sCD137 and troponin T by ELISA
sCD137 levels were determined by ELISA. The intra-assay
and inter-assay coefficients of variation were ,9%. The
concentrations of troponin I were determined using the
Triage and Biosite system (lower detection limit of 0.04 ng/
ml).
Detection of platelet activation
In vivo platelet activation was performed as previously
described (12). Briefly, peripheral venous blood was
collected in tubes containing sodium citrate. Circulating
monocyte-platelet aggregates indicated activation of the
platelets. Monocyte-platelet aggregates were defined as
monocytes that were positive for glycoprotein IIIa using a
CD61 monoclonal antibody. The values are expressed as the
percent of aggregated monocytes.
Statistical analysis
Statistical evaluation was performed using Graph Pad
software (Prism 3.0) and the univariate program in SPSS
11.5 software. Data are expressed as the mean¡SD.
Differences between groups were analyzed by one-way
ANOVA (post-hoc LSD). Spearman rank correlation was
used to assess the relationship between two quantitative
variables with non-normal distribution. The Wilcoxon rank-
sum test was used to compare the levels of sCD137 between
cases with and without clinical end points. Univariate and
multivariate associations were analyzed using the Cox
proportional hazards model to evaluate the independent
contributions of variables at the nine-month follow-up to the
risk of MACEs. All hazard ratios were adjusted for diabetes,
hypertension, hypercholesterolemia and cTnI. p-values less
than 0.05 were considered to be significant.
& RESULTS
Baseline sCD137 and adverse events in patients with
ACS
The 180 patients with ACS were classified according to
their baseline levels of sCD137. There were 31 patients in the
first group (10.0-20.0 ng/ml), 74 patients in the second
group (20.0-35.0 ng/ml) and 75 patients in the third group
(.35.0 ng/ml). Elevated sCD137 levels (.35.0 ng/ml)
indicated an increased risk for MACEs (odd’s ratio
(OR) = 1.93, 95% confidence interval (CI): 1.39-2.54). There
were no significant differences in the baseline characteristics
of the three groups (Table 1). At the 30-day, six-month and
nine-month follow-ups, the rates of MACE were signifi-
cantly higher in the second and third groups (Figure 1).
Multivariate analysis using sCD137 as a continuous variable
revealed that the sCD137 levels (.35.0 ng/ml) were
associated with a higher risk of AMI (RR= 2.18, 95% CI:
1.27-4.25, p= 0.011), sudden death (RR= 1.82, 95% CI: 1.13-
3.58, p= 0.031) and recurrent angina (RR= 2.63, 95% CI: 1.41-
5.03, p= 0.019).
Prognostic value of sCD137 combined with cTnI
We observed a significant correlation between sCD137
levels and cTnI levels (r = 0.4799, p,0.001 n= 154, Figure 2A).
At the 30 day, six month and nine month follow-ups,
patients with high levels of sCD137 and cTnI had a
markedly increased risk of MACE. Patients with low levels
of sCD137L and cTnI had a low rate of MACE. Of the 26
cTnI-negative subjects (,0.04 ng/ml) with ACS, increased
sCD137 levels identified a subgroup of high-risk patients
within these cTnI-negative patients (OR= 2.14, 95% CI: 1.25-
4.13) (Figure 2B).
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Prospective validation of patients with acute chest
pain in the emergency room
Of the 102 patients with acute chest pain, 59 patients had
ACS. The remaining 43 patients had congestive heart failure,
stable angina or no evidence of heart disease. Serum sCD137
levels were significantly higher in the 59 patients with ACS
(Figure 3A). A total of 20 patients had high levels of sCD137
(.35.0 ng/ml). Using receiver operating characteristic (ROC)
curves, we identified a positive value for predicting ACS
using the sCD137 level. The area under the curve (AUC) was
0.858¡0.04 (95% CI, 0.783-0.934; p,0.001, Figure 3B). Based
on the ROC curve, we derived an optimal cutoff value of
21.5 ng/ml for sCD137. Levels of sCD137 above or below this
cutoff value were associated with MACE rates of 23.6% and
5.1%, respectively (p,0.001, Figure 3C). The sensitivity was
76.3%, the specificity was 78.3%, and the negative predictive
value was 99%. We observed a strong correlation between
platelet activation, as evidenced by the percent of monocyte-
platelet aggregates, and sCD137 levels in the subgroup of 59
ACS patients (r = 0.6511, p,0.0001, n= 59, Figure 3D).
Multivariable analysis
After adjusting for baseline characteristics, the patients
with sCD137 levels .21.5 ng/ml continued to be at
increased risk for MACE (HR 2.32, 95% CI 1.72-3.18,
p,0.001). After adding cTnI to the multivariable model,
Table 1 - Baseline characteristics according to sCD137 levels.
Groups Low (n=31) Middle (n= 74) High (n = 75) p-value
(10.0-20.0 ng/ml) (20.0-35.0 ng/ml) (.35.0 ng/ml)
Age , Y 62.1¡10.4 61.7¡11.7 62.4¡11.8 0.15
Sex, M/F 19/12 45/29 46/29 0.34
Risk factors, %
Diabetes 12.9 12.2 13.4 0.86
Hypertension 25.8 25.7 26.7 0.77
Hypercholesterolemia 9.7 9.5 10.7 0.53
Smoking 22.6 23.0 22.7 0.51
Clinical history, %
STEMI 42.0 41.9 42.7 0.61
NSTEMI 29.1 28.4 29.4 0.47
UA 28.9 29.7 27.9 0.83
Prior medication, %
Aspirin 93.6 93.3 93.4 0.94
Statin 22.6 23.0 22.7 0.58
Beta-blockers 71.0 70.3 70.7 0.61
ACEI 45.2 44.6 45.4 0.71
STEMI: ST-elevation myocardial infarction. NSTEMI: non-ST-elevation myocardial infarction. UA: unstable angina. ACEI: angiotensin-converting enzyme inhibitor.
Figure 1 - The relationship between baseline sCD137 levels and the
rate of major adverse cardiovascular events (MACEs) at 30 days, 6
and 9months in 180 patientswith ACS. Data are presented as bars;
the bar length represents the mean value for each group, and the
error bars show the standard error of the mean.
Figure 2 - Prognostic value of baseline sCD137 combined with
cTnI. A) Correlation between baseline sCD137 and cTnI levels. B)
Combined assessment of baseline sCD137 and cTnI assists in risk
prediction at follow-up.
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the relationship between sCD137 and MACE remained
significant (HR 2.61, 95% CI 1.93-3.52, p,0.001) (Table 2).
& DISCUSSION
A number of biochemical markers provide important
insights into different aspects of the pathobiology of ACS
and are used to assist in risk stratification following a
cardiovascular event. In this study, sCD137 levels assisted
in identifying patients who were at an increased risk of
MACE. This marker may provide an additional pathophy-
siological procedure for evaluating patients with ACS.
Increasing evidence has suggested that the CD137-
CD137L system plays an important role in coronary disease
progression and plaque destabilization. In vitro and in vivo
studies have demonstrated a crucial role for CD137 at
Figure 3 - Baseline sCD137 levels and platelet activation in patients with acute chest pain. A) The baseline sCD137 levels in patients with
ACS, congestive heart failure, stable angina and no evidence of heart disease. B) ROC curves for predicting ACS using sCD137. C: MACE
rate relative to sCD137 values. D: The correlation between baseline sCD137 levels and monocyte-platelet aggregates.
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multiple stages of atherosclerosis and ACS (11,13). We
recently demonstrated that patients with ACS showed
increased expression of soluble and membrane-bound
CD137 (which marks peripheral). We also observed a
significant correlation between CD137 levels and complex
coronary stenoses in patients with ACS (10). These data
suggest that increased CD137 may be a reliable biomarker
for coronary disease and may also play an important role in
disrupting vulnerable atherosclerotic plaques in ACS.
In the present study, the rates of MACE were significantly
higher in the second (sCD137, 20.0-35.0 ng/ml) and third
ACS groups (sCD137, .35.0 ng/ml). The levels of sCD137L
were significantly correlated with cTnI levels in ACS
patients. However, in the 26 cTnI-negative subjects with
ACS, high sCD137 levels identified patients who were at
risk for MACE and were not detected by cTnI (,0.04 ng/
ml) alone. Patients with normal cTnI levels and increased
sCD137 levels were at an increased risk for cardiovascular
events. In the cTnI-negative ACS patients, the cumulative
nine-month MACE was 7.9%. These results suggest that
measuring circulating sCD137 can provide efficient risk
assessments in such patients. A single measurement of
sCD137 at the time of hospital admission showed significant
predictive power for future cardiovascular events.
However, the kinetics of sCD137 release and the corre-
sponding optimal sampling protocols for ACS should be
standardized.
Cardiac troponin markers for myocardial necrosis have
become the gold standard biochemical marker for diagnos-
ing and determining the prognosis in patients with ACS
(1,14,15). However, these markers are not indicative of the
pathophysiology of ACS and unstable plaques. In contrast,
CD137 may be directly involved in the underlying mechan-
isms that disrupt the vulnerable plaques in ACS. Recent
evidence suggests that CD137-CD137L interactions contri-
bute to the progression of atherosclerotic plaques (16,17). In
this study, sCD137 was a reliable prognostic marker that
provided additional information to the troponin I results.
Multivariable modeling suggested that sCD137 offers
prognostic information independent of other clinical pre-
dictors. After cTnI was added to the multivariable model,
the relationship between sCD137 and MACE remained
significant.
ACS results from the disruption of atherosclerotic
plaques, leading to coronary thrombosis. Platelet activation
is the core of thrombus formation, which precipitates the
majority of unstable plaques and coronary syndromes. A
previous study demonstrated that circulating monocyte-
platelet aggregates are a more sensitive marker of in vivo
platelet activation than platelet surface P-selectin, which is
considered to be the "gold standard" marker of platelet
activation (12). In the acute chest pain group, platelet
activation was closely correlated with sCD137 levels in
patients with ACS. Thus, sCD137 not only contributes to the
pathophysiology of ACS but also represents a reliable and
powerful clinical marker for identifying patients with high-
risk atherosclerotic lesions and coronary thrombosis.
In summary, the results of the present study demonstrate
that elevated levels of sCD137 are associated with increased
cardiac risk. The predictive value of sCD137 levels was
independent of elevated troponin I levels. Increased sCD137
levels are a marker of plaque instability that favors
progression to ACS and are indicative of a poor prognosis
even after the occurrence of an acute ischemic event caused
by plaque instability. However, the use of elevated sCD137
as a tool to guide therapy should be further elucidated. The
relatively small number of patients in this study should be
taken into account. Studies using a larger cohort of patients
should be performed to establish the clinical use of sCD137
independently of or in combination with other markers to
predict cardiovascular events after ACS.
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